VICP logo

Vicapsys Life Sciences OTCPK:VICP Stock Report

Last Price

US$1.99

Market Cap

US$63.8m

7D

0%

1Y

n/a

Updated

15 Mar, 2024

Data

Company Financials

Vicapsys Life Sciences, Inc.

OTCPK:VICP Stock Report

Market Cap: US$63.8m

VICP Stock Overview

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product.

VICP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Vicapsys Life Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vicapsys Life Sciences
Historical stock prices
Current Share PriceUS$1.99
52 Week HighUS$3.00
52 Week LowUS$1.03
Beta-5.95
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change-17.43%
Change since IPO-43.14%

Recent News & Updates

Recent updates

Shareholder Returns

VICPUS BiotechsUS Market
7D0%-1.6%-0.3%
1Yn/a10.2%28.4%

Return vs Industry: Insufficient data to determine how VICP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VICP performed against the US Market.

Price Volatility

Is VICP's price volatile compared to industry and market?
VICP volatility
VICP Average Weekly Movementn/a
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: VICP's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine VICP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972Fred Pierhttps://vicapsys.com

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.

Vicapsys Life Sciences, Inc. Fundamentals Summary

How do Vicapsys Life Sciences's earnings and revenue compare to its market cap?
VICP fundamental statistics
Market capUS$63.82m
Earnings (TTM)-US$1.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

-59.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VICP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.08m
Earnings-US$1.08m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.034
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-23.0%

How did VICP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.